AI assistant
BIO-RAD LABORATORIES, INC. — Director's Dealing 2023
Apr 11, 2023
30786_dirs_2023-04-11_c65882fa-9ef5-4601-b36e-40f0f6434a82.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIO-RAD LABORATORIES, INC. (BIO BIOB)
CIK: 0000012208
Period of Report: 2023-04-08
Reporting Person: Daskal Ilan (EVP, Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-04-08 | Bio-Rad A Common Stock | M | 700 | — | Acquired | 1736.2680 | Direct |
| 2023-04-08 | Bio-Rad A Common Stock | F | 243 | $466.24 | Disposed | 1493.2680 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-04-08 | Restricted Stock Units | $0 | M | 700 | Disposed | Bio-Rad A Common Stock (700) | Direct |
Footnotes
F1: Shares of Class A common stock acquired on the vesting of restricted stock units.
F2: Includes 44.9320 and 38.3360 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 12/30/2022 and 3/31/2023, respectively.
F3: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
F4: On April 8, 2019, the reporting person was granted 3,500 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date.